- Company
- 1 in 3 don't know the right dose of antipyretic drugs
- by Apr 20, 2022 06:05am
- With COVID-19, 9 out of 10 consumers have purchased antipyretic drugs within the past six months, but one in three still does not know the appropriate dosage, indicating that appropriate medication guidance is needed. Johnson & Johnson Korea announced the results of a survey conducted on 1,000 consumers aged 20 to 49 in Korea on the 18th through
- Company
- Hanmi leads the outpatient prescription market in Q1 2022
- by Chon, Seung-Hyun Apr 19, 2022 05:53am
- Hanmi Pharmaceutical’s performance stood out in the outpatient prescription market with its solidified lead heralded by the introduction of its new combination drug. Daewon Pharmaceutical’s prescription volume has also soared vertically due to the boom in anti-inflammatory and cold medicines following a surge in the number of confirmed COVID-1
- Company
- The prolonged slump in IPO of pharmaceutical bio
- by Kim, Jin-Gu Apr 19, 2022 05:52am
- Amid the prolonged sluggish trend in the IPO market in the pharmaceutical bio industry, attention is being paid to whether newly challenged companies will be able to draw a turnaround. According to the pharmaceutical industry on the 19th, there are two pharmaceutical bio companies that have been listed in the second quarter of this year, Wont
- Company
- Pharmaceutical industry starts face-to-face marketing
- by Kim, Jin-Gu Apr 18, 2022 05:58am
- As the government decided to completely lift social distancing measures from today (18th), the pharmaceutical bio industry is also actively planning offline marketing events. As large-scale offline events have been virtually impossible for nearly two years, marketers are raising expectations for changes caused by the move. ◆ Abolish so
- Company
- DHP Korea faces reimb. reevaluations for its HA eye drops
- by Nho, Byung Chul Apr 18, 2022 05:58am
- How DHP Korea, a company specializing in eye drops, will be establishing a strategy to defend its sales ahead of the upcoming reimbursement reevaluations for its HA (hyaluronic acid) products next year is drawing attention. In particular, this upcoming risk is highly likely to serve as a testbed to verify the company’s newly appointed CEO Eu
- Company
- Dividend payout for Pfizer is 12.48 million won
- by Chon, Seung-Hyun Apr 15, 2022 06:03am
- Pfizer Pharmaceutical Korea performed better last year with sales of the COVID-19 vaccine, but its dividend was only 12.48 million won. Regardless of the sharp rise in performance, the dividend payout ratio was only 0.01%, allocating 20% of the capital of preferred stocks. It has adhered to a unique dividend policy that distributes 12.48 million
- Company
- Acromegaly drug ‘Somavert’ lands in ‘Big 5’ hospitals
- by Eo, Yun-Ho Apr 15, 2022 06:03am
- The new acromegaly drug ‘Somavert’ may now be prescribed at general hospitals in Korea. According to industry sources, Pfizer Korea’s Somavert (pegvisomant) has passed the review of Drug Committees at the ‘Big 5’ tertiary hospitals in Korea including the Samsung Medical Center, Seoul National University Hospital, Seoul St.Mary’s Hos
- Company
- Artiva expands contract to develop dell therapy with MSD
- by Eo, Yun-Ho Apr 15, 2022 06:03am
- GC Pharma affiliate Artiva Biotheraputics announced on the 12th that it has signed a contract with MSD to expand the development of natural killing (NK) cell therapy. Artiva was established in 2019 by GC CELL and GC LABTECH in San Diego, USA. Under the contract, the two companies will promote joint research on anticancer drugs that combine NK
- Company
- Somavert for terminal hypertrophy can be prescribed at Big 5
- by Eo, Yun-Ho Apr 14, 2022 05:56am
- Somavert, a new drug for terminal hypertrophy, can be prescribed at a general hospital. According to related industries, Pfizer Korea's Somavert has currently passed DC of the Big 5 higher-level medical institutions such as Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, AMC, and Sinchon Severance Hospit
- Company
- “NOAC Eliquis is safe for use in high-risk groups”
- by Apr 13, 2022 06:02am
- The bleeding safety of the novel oral anticoagulant (NOAC) ‘Eliquis (apixaban)’ was reaffirmed through clinical practice guidelines of major academic societies. On the 12th, BMS Korea and Pfizer Korea announced that they have hosted a ‘VMC Master of Masters Webinar’ on the 11th to share the latest advances in preventive therapies for
